2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      All over the map: An interobserver agreement study of tumor location based on the PI-RADSv2 sector map : Agreement on Prostate mpMRI PI-RADS Map

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Prostate imaging reporting and data system version 2 (PI-RADSv2) recommends a sector map for reporting findings of prostate cancer mulitparametric MRI (mpMRI). Anecdotally, radiologists may demonstrate inconsistent reproducibility with this map. To evaluate interobserver agreement in defining prostate tumor location on mpMRI using the PI-RADSv2 sector map. Retrospective. Thirty consecutive patients who underwent mpMRI between October, 2013 and March, 2015 and who subsequently underwent prostatectomy with whole-mount processing. 3T mpMRI with T 2 W, diffusion-weighted imaging (DWI) (apparent diffusion coefficient [ADC] and b -2000), dynamic contrast-enhanced (DCE). Six radiologists (two high, two intermediate, and two low experience) from six institutions participated. Readers were blinded to lesion location and detected up to four lesions as per PI-RADSv2 guidelines. Readers marked the long-axis of lesions, saved screen-shots of each lesion, and then marked the lesion location on the PI-RADSv2 sector map. Whole-mount prostatectomy specimens registered to the MRI served as ground truth. Index lesions were defined as the highest grade lesion or largest lesion if grades were equivalent. Agreement was calculated for the exact, overlap, and proportion of agreement. Readers detected an average of 1.9 lesions per patient (range 1.6–2.3). 96.3% (335/348) of all lesions for all readers were scored PI-RADS ≥3. Readers defined a median of 2 (range 1–18) sectors per lesion. Agreement for detecting index lesions by screen shots was 83.7% (76.1%–89.9%) vs. 71.0% (63.1–78.3%) overlap agreement on the PI-RADS sector map ( P < 0.001). Exact agreement for defining sectors of detected index lesions was only 21.2% (95% confidence interval [CI]: 14.4–27.7%) and rose to 49.0% (42.4–55.3%) when overlap was considered. Agreement on defining the same level of disease (ie, apex, mid, base) was 61.4% (95% CI 50.2–71.8%). Readers are highly likely to detect the same index lesion on mpMRI, but exhibit poor reproducibility when attempting to define tumor location on the PI-RADSv2 sector map. The poor agreement of the PI-RADSv2 sector map raises concerns its utility in clinical practice. 3 Stage 2

          Related collections

          Most cited references8

          • Record: found
          • Abstract: not found
          • Article: not found

          The zonal anatomy of the prostate

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Current status of MRI for the diagnosis, staging and prognosis of prostate cancer: implications for focal therapy and active surveillance.

            To review the current status of MRI techniques in identification of organ-confined prostate cancer with a focus on their implication for focal therapy and active surveillance. MRI is currently focusing on intraprostatic prostate cancer identification and at 1.5T, it provides excellent imaging of the whole gland including the challenging anterior part. Improvements in accuracy for cancer detection and volume estimation result from dynamic contrast-enhanced and diffusion-weighted MRI sequences. 3T MRI might improve cancer identification. Histological correlations showed high sensitivity and specificity for significant volume cancers larger than 0.5 cm3. Important knowledge on modelling of cancer morphology such as zone of origin and intraprostatic patterns of spread at histopathology was made available for imaging interpretation and treatment planning decision. MRI results allow focused use of biopsy which led to better cancer characterization such as extent and grade. Ongoing focal therapy protocols and active surveillance treatments should benefit from these imaging advances. At present, high-resolution MRI with pelvic coil appears to offer the most readily available and useful imaging. Future studies should work towards helping define standard, reproducible approaches to imaging and image reporting for research and clinical practice.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Recent advances in image-guided targeted prostate biopsy

              Prostate cancer is a common malignancy in the United States that results in over 30,000 deaths per year. The current state of prostate cancer diagnosis, based on PSA screening and sextant biopsy, has been criticized for both overdiagnosis of low grade tumors and underdiagnosis of clinically significant prostate cancers (Gleason score ≥ 7). Recently, image guidance has been added to perform targeted biopsies of lesions detected on multi-parametric magnetic resonance imaging (mpMRI) scans. These methods have improved the ability to detect clinically significant cancer, while reducing the diagnosis of low grade tumors. Several approaches have been explored to improve the accuracy of image-guided targeted prostate biopsy, including in-bore MRI-guided, cognitive fusion, and MRI/transrectal ultrasound fusion-guided biopsy. This review will examine recent advances in these image-guided targeted prostate biopsy techniques.
                Bookmark

                Author and article information

                Journal
                Journal of Magnetic Resonance Imaging
                J. Magn. Reson. Imaging
                Wiley
                10531807
                August 2018
                August 2018
                January 17 2018
                : 48
                : 2
                : 482-490
                Affiliations
                [1 ]Molecular Imaging Program, NCI; NIH; Bethesda Maryland USA
                [2 ]Biometric Research Program, NCI; NIH; Bethesda Maryland USA
                [3 ]University of Cambridge School of Medicine, Department of Radiology; Cambridge UK
                [4 ]Institute of Diagnostic Radiology, Department of Medical Area; University of Udine; Udine Italy
                [5 ]Hacettepe University; Ankara Turkey
                [6 ]Singapore General Hospital; Singapore
                [7 ]Department of Radiology, Urology Center; Mansoura University; Mansoura Egypt
                [8 ]Laboratory of Pathology, NCI; NIH; Bethesda Maryland USA
                [9 ]Center for Interventional Oncology, NCI and Radiology Imaging Sciences, Clinical Center; NIH; Bethesda Maryland USA
                [10 ]Urologic Oncology Branch, NCI; NIH; Bethesda Maryland USA
                Article
                10.1002/jmri.25948
                7983160
                29341356
                edd7982c-0181-438d-b3d1-c1e065131d7b
                © 2018

                http://doi.wiley.com/10.1002/tdm_license_1.1

                http://onlinelibrary.wiley.com/termsAndConditions#vor

                History

                Comments

                Comment on this article